Research
Molecular
The reductions in TG levels persisted at 26 weeks with a mean treatment difference of -12.7% compared to placebo.
ω-3-PL/FFA may provide long-term benefits in managing TG levels.
StrongSupportsmedium confidence
Reductions persisting at 26 weeks (mean treatment difference, -12.7% [95% CI, -23.1% to -2.4%]; P = .02).
Why this rating
Based on the large randomized controlled trial design.
Source
Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia
Dariush Mozaffarian et al. · JAMA Network Open · 2022
rct · n=520Cited 24×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →